tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

BIIB Stock Latest News

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
Press ReleasesBiogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS
23h ago
BIIB
FDA Peripheral/Central Nervous System Drugs Advisory Committee holds meeting
The FlyFDA Peripheral/Central Nervous System Drugs Advisory Committee holds meeting
1d ago
BIIB
Inozyme appoints Matthew Winton as COO
The FlyInozyme appoints Matthew Winton as COO
1d ago
BIIB
INZY
FDA Peripheral/Central Nervous System Drugs Advisory Committee holds meeting
The FlyFDA Peripheral/Central Nervous System Drugs Advisory Committee holds meeting
2d ago
BIIB
FDA Peripheral/Central Nervous System Drugs Advisory Committee holds meeting
The FlyFDA Peripheral/Central Nervous System Drugs Advisory Committee holds meeting
2d ago
BIIB
FDA briefing docs suggest FDA in favor of Biogen’s tofersen, says BofA
The FlyFDA briefing docs suggest FDA in favor of Biogen’s tofersen, says BofA
2d ago
BIIB
FDA posts briefing document for advisors’ review of Biogen’s ALS drug
The FlyFDA posts briefing document for advisors’ review of Biogen’s ALS drug
3d ago
BIIB
Stifel trims Biogen target, but has more confidence lecanemab ‘best-in-class’
The FlyStifel trims Biogen target, but has more confidence lecanemab ‘best-in-class’
6d ago
LLY
BIIB
Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
Press ReleasesBiogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection
8d ago
BIIB
Biogen receives favorable court ruling on TECFIDERA
The FlyBiogen receives favorable court ruling on TECFIDERA
8d ago
BIIB
Needham healthcare analyst to hold an analyst/industry conference call
The FlyNeedham healthcare analyst to hold an analyst/industry conference call
8d ago
LLY
BIIB
Needham healthcare analyst to hold an analyst/industry conference call
The FlyNeedham healthcare analyst to hold an analyst/industry conference call
9d ago
LLY
BIIB
Biogen Appoints Chuck Triano as Head of Investor Relations
Press ReleasesBiogen Appoints Chuck Triano as Head of Investor Relations
9d ago
BIIB
Biogen appoints Triano as Head of Investor Relations
The FlyBiogen appoints Triano as Head of Investor Relations
9d ago
BIIB
Biogen ‘welcomes’ VHA recent decision to provide coverage to Leqembi
The FlyBiogen ‘welcomes’ VHA recent decision to provide coverage to Leqembi
10d ago
BIIB
VA to widely cover new Alzheimer’s treatment from Eisai and Biogen, STAT says
The FlyVA to widely cover new Alzheimer’s treatment from Eisai and Biogen, STAT says
10d ago
BIIB
Biogen price target raised to $350 from $335 at RBC Capital
The FlyBiogen price target raised to $350 from $335 at RBC Capital
11d ago
BIIB
Needham healthcare analyst to hold an analyst/industry conference call
The FlyNeedham healthcare analyst to hold an analyst/industry conference call
14d ago
LLY
BIIB
No ad com suggests positive potential outcome for Sage’s zura, says BofA
The FlyNo ad com suggests positive potential outcome for Sage’s zura, says BofA
14d ago
BIIB
SAGE
Biogen elects Dorsa as Chair of the Board of Directors
The FlyBiogen elects Dorsa as Chair of the Board of Directors
15d ago
BIIB
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
Press ReleasesCaroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
15d ago
BIIB
Biogen, Sage Therapeutics: FDA has no plans to discuss NDA for zuranolone
The FlyBiogen, Sage Therapeutics: FDA has no plans to discuss NDA for zuranolone
16d ago
BIIB
SAGE
Eisai, Biogen say FDA accepted sBLA for LEQEMBI, granted Priority Review
The FlyEisai, Biogen say FDA accepted sBLA for LEQEMBI, granted Priority Review
18d ago
BIIB
FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Press ReleasesFDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
18d ago
BIIB
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
Press ReleasesBiologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
24d ago
BIIB
Biogen license application for lecanemab designated for priority review in China
The FlyBiogen license application for lecanemab designated for priority review in China
24d ago
BIIB
Biogen price target lowered to $333 from $359 at RBC Capital
The FlyBiogen price target lowered to $333 from $359 at RBC Capital
1M ago
BIIB
Biogen price target raised to $315 from $300 at Cowen
The FlyBiogen price target raised to $315 from $300 at Cowen
1M ago
BIIB
Biogen price target raised to $351 from $345 at Morgan Stanley
The FlyBiogen price target raised to $351 from $345 at Morgan Stanley
1M ago
BIIB
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.